Steward Partners Investment Advisory, LLC Supernus Pharmaceuticals, Inc. Transaction History

Steward Partners Investment Advisory, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	SELL	$31.09 - $37.88 $777 - $947	-25 Reduced 17.61%	117 $4,000
Q3 2022 Nov 10, 2022	BUY	$28.79 - $35.41 $719 - $885	25 Added 21.37%	142 $5,000
Q4 2021 Feb 08, 2022	SELL	$26.37 - $34.22 $395 - $513	-15 Reduced 11.36%	117 $3,000
Q2 2021 Aug 13, 2021	SELL	$26.72 - $33.19 $13,360 - $16,595	-500 Reduced 79.11%	132 $4,000
Q1 2021 May 14, 2021	BUY	$24.15 - $31.45 $12,075 - $15,725	500 Added 378.79%	632 $16,000
Q2 2020 Aug 06, 2020	SELL	$17.09 - $24.89 $1,726 - $2,513	-101 Reduced 43.35%	132 $3,000
Q1 2020 Apr 29, 2020	SELL	$14.45 - $24.69 $2,890 - $4,938	-200 Reduced 46.19%	233 $4,000
Q4 2019 Jan 17, 2020	SELL	$19.93 - $29.13 $3,986 - $5,826	-200 Reduced 31.6%	433 $10,000
Q3 2019 Oct 30, 2019	BUY	$25.47 - $33.37 $382 - $500	15 Added 2.43%	633 $17,000
Q2 2019 Jul 25, 2019	BUY	$29.96 - $38.87 $18,515 - $24,021	618 New	618 $20,000
Q4 2018 Jan 15, 2019	SELL	$30.84 - $49.51 $9,776 - $15,694	-317 Closed	0 $0
Q3 2018 Oct 23, 2018	BUY	$42.7 - $56.55 $8,540 - $11,310	200 Added 170.94%	317 $16,000
Q1 2017 Nov 22, 2017	BUY	N/A	117	117 $3,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.